Madrigal Pharmaceuticals Gains Patent Control for Rezdiffra in Amended Roche Agreement
I'm PortAI, I can summarize articles.
Madrigal Pharmaceuticals Inc. has amended its agreement with F. Hoffmann-La Roche Ltd, granting it full control over patent term adjustments and extensions for Rezdiffra. This includes patents owned or jointly owned by Roche. Additionally, royalty payments to Roche based on Rezdiffra's net sales will remain unchanged until certain patent term extensions expire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments